List view / Grid view
25 June 2015 | By Victoria White
The European Commission (EC) has granted Marketing Authorisation for Daiichi Sankyo’s Lixiana, an oral, once-daily selective factor Xa-inhibitor...
2 June 2015 | By Victoria White
The Future of Anticoagulation Report highlights that urgent action is critical to lessening the potential impact of atrial fibrillation...
29 April 2015 | By Victoria White
A recent survey has found that 52% of 275 ACS patients who were currently taking an oral antiplatelet have missed taking or changed the way they take it...
15 April 2015 | By Daiichi Sankyo
Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation...
25 March 2015 | By Victoria White
Daiichi Sankyo have announced that the Sun Pharma and Ranbaxy merger process has been completed...
20 March 2015 | By Victoria White
Daiichi Sankyo has announced a co-commercialisation agreement with AstraZeneca for MOVANTIK™ (naloxegol) in the US with plans to launch in April 2015..
9 January 2015 | By Daiichi Sankyo
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism...
8 December 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets...
1 October 2014 | By Daiichi Sankyo
Daiichi Sankyo Company Limited announced that it and its domestic generic subsidiary, Daiichi Sankyo Espha Co., Ltd. have submitted a supplemental New Drug Application (sNDA) in Japan...
3 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation...
2 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced details of the application for its Take a New Challenge for Drug Discovery Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe...
2 September 2014 | By Daiichi Sankyo
A SGLT2 inhibitor for Type2 Diabetes Mellitus...
28 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute on August 22 for its recombinant adsorbed hepatitis B vaccine (yeast-derived), Bimmugen®...
18 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar1, in rheumatoid arthritis (the RApsody trial) in Japan...
7 August 2014 | By Daiichi Sankyo
... to develop and commercialize novel, fixed-dose combination hydrocodone products for pain and opioid-induced nausea and vomiting in the US.
